Introduction {#Sec1}
============

Diabetic nephropathy is a serious microvascular complication of diabetes, and is a leading cause of end-stage renal disease in Western countries \[[@CR1]\] and in Japan \[[@CR2]\]. The escalating prevalence and limitation of currently available therapeutic options highlight the need for a more accurate understanding of the pathogenesis of diabetic nephropathy. Several environmental factors, such as medication, daily energy consumptions, and daily sodium intake, are likely to cooperate with genetic factors to contribute to its development and progression \[[@CR3], [@CR4]\]; however, the precise mechanism for this contribution is unknown. Krolewski et al. \[[@CR5]\] reported that the cumulative incidence of diabetic retinopathy increased linearly with duration of diabetes, whereas the occurrence of nephropathy was almost none after 20--25 years of diabetes duration, and only a modest number of individuals with diabetes (\~30%) developed diabetic nephropathy. Familial clustering of diabetic nephropathy was also reported in both type 1 \[[@CR4]\] and type 2 diabetes \[[@CR6]\]; thus, the involvement of genetic factors in the development of diabetic nephropathy is strongly suggested. Both candidate gene approaches and genome-wide linkage analyses have suggested several candidate genes with a potential impact on diabetic nephropathy. These findings, however, have not been robustly replicated and many genes responsible for susceptibility to diabetic nephropathy remain to be identified. To identify loci involved in susceptibility to common diseases, we initiated the first round of a genome-wide association study (GWAS) using 100,000 single nucleotide polymorphisms (SNPs) from a Japanese SNP database (JSNP: <http://snp.ims.u-tokyo.ac.jp/index_ja.html>). Through this project, we have previously identified genes encoding solute carrier family 12 (sodium/chloride) member 3 (*SLC12A3*, MIM 600968, Online Mendelian Inheritance in Man: <http://www.ncbi.nlm.nih.gov/omim>) \[[@CR7]\]; engulfment and cell motility 1 (*ELMO1*, MIM 606420) \[[@CR8]\]; neurocalcin δ (*NCALD*, MIM 606722) \[[@CR9]\]; and acetyl-coenzyme A carboxylase beta gene (*ACACB*, MIM: 601557) \[[@CR10]\] as being associated with susceptibility to diabetic nephropathy. The association between *ELMO1* or *ACACB* and diabetic nephropathy has been confirmed in different ethnic populations \[[@CR11]--[@CR13]\]. The GWAS for diabetic nephropathy using European American populations (the Genetics of Kidneys in Diabetes (GoKinD) collection) led to the identification of 4 distinct loci as novel candidate loci for susceptibility to diabetic nephropathy in European American subjects with type 1 diabetes \[[@CR14]\]: the *CPVL*/*CHN2* locus on chromosome 7, the *FRMD3* locus on chromosome 9, the *CARS* locus on chromosome 11, and a locus near *IRS2* on chromosome 13. Among those 4 loci, only one locus (near *IRS2* in chromosome 13) could be replicated in Japanese subjects with type 2 diabetes \[[@CR15]\]. Although these loci are considered as convincing susceptibility loci for diabetic nephropathy across different ethnic groups, a considerable number of susceptibility genes for diabetic nephropathy still remain to be identified.

Sirtuins, the silent information regulator-2 (SIR2) family, is a member of NAD-dependent deacetylases, and the *sir2* gene was originally identified as a gene affecting the malting ability of yeast. Mammalian sirtuins consist of seven members, SIRT1--SIRT7, and some of them, especially SIRT1, have been shown to play pivotal roles in the regulation of aging, longevity, or in the pathogenesis of age-related metabolic diseases, such as type 2 diabetes \[[@CR16]--[@CR18]\]. The expressions of sirtuin families have also been observed in the kidneys, and recently SIRT1 has been shown to mediate a protective role of calorie restriction (CR) in the progression of the aging kidney \[[@CR19]\]. These observations suggest the possibility that mammalian sirtuins are a candidate for conferring susceptibility to diabetic nephropathy.

In order to test this hypothesis, we focused on genes encoding mammalian sirtuins as candidate genes for diabetic nephropathy and investigated the association between SNPs within the SIRT genes and diabetic nephropathy in Japanese subjects with type 2 diabetes.

Materials and methods {#Sec2}
=====================

Subjects, DNA preparation {#Sec3}
-------------------------

### Study 1 {#Sec4}

DNA samples were obtained from the peripheral blood of patients with type 2 diabetes who regularly visited the outpatient clinic at Shiga University of Medical Science, Tokyo Women's Medical University, Juntendo University, Kawasaki Medical School, Iwate Medical University, Toride Kyodo Hospital, Kawai Clinic, Osaka City General Hospital, Chiba Tokushukai Hospital, or Osaka Rosai Hospital. Diabetes was diagnosed according to the World Health Organization criteria. Type 2 diabetes was clinically defined as a disease with gradual adult onset. Subjects who tested positive for anti-glutamic acid decarboxylase antibodies and those diagnosed with mitochondrial disease (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS)) or maturity onset diabetes of the young were not included. The patients were divided into 2 groups: (1) the nephropathy group (*n* = 754, age 60.1 ± 0.4, diabetes duration 19.3 ± 0.4, body mass index (BMI) 23.7 ± 0.2, mean ± SE) comprised patients with diabetic retinopathy and overt nephropathy indicated by a urinary albumin excretion rate (AER) ≥200 μg/min or a urinary albumin/creatinine ratio (ACR) ≥300 mg/g creatinine (Cr), and (2) the control group (*n* = 558, age 62.4 ± 0.5, diabetes duration 15.3 ± 0.4, BMI 23.6 ± 0.2) comprised patients who had diabetic retinopathy but no evidence of renal dysfunction (i.e. AER \<20 μg/min or ACR \<30 mg/g Cr). The AER or ACR were measured at least twice for each patient.

### Study 2 {#Sec5}

We selected diabetic nephropathy patients and control patients among the subjects enrolled in the BioBank Japan. Nephropathy cases were defined as patients with type 2 diabetes having both overt diabetic nephropathy and diabetic retinopathy (*n* = 449, age 64.7 ± 0.4, BMI 23.5 ± 0.2). The control subjects were patients with type 2 diabetes who had diabetic retinopathy and normoalbuminuria (*n* = 965, age 64.8 ± 0.3, BMI 23.8 ± 0.1).

### Study 3 {#Sec6}

Patients with type 2 diabetes who regularly visited Tokai University Hospital or its affiliated hospitals were enrolled in this study. All the nephropathy patients (*n* = 300, age 64.4 ± 0.6, diabetes duration 21.9 ± 0.9, BMI 22.1 ± 0.2, mean ± SE) were receiving chronic hemodialysis therapy, and the control patients (*n* = 224, age 65.0 ± 0.7, diabetes duration 16.3 ± 0.4, BMI 23.4 ± 0.3, mean ± SE) included those with normoalbuminuria as determined by at least 2 measurements of urinary ACR and with diabetes for \>10 years.

All the patients participating in this study provided written informed consent, and the study protocol was approved by the ethics committees of RIKEN Yokohama Institute and of each participating institution.

The clinical characteristics of the subjects are shown in Supplementary Table 1.

SNP genotyping {#Sec7}
--------------

We searched the HapMap database (<http://hapmap.ncbi.nlm.nih.gov/>) for SNPs within the genes encoding sirtuin families, and selected 55 SNPs (39 tagging SNPs) for genotyping; 11 in *SIRT1* (rs12778366, rs3740051, rs2236318, rs2236319, rs10823108, rs10997868, rs2273773, rs3818292, rs3818291, rs4746720, rs10823116), 7 in *SIRT2* (rs1001413, rs892034, rs2015, rs2241703, rs2082435, rs11575003, rs2053071), 15 in *SIRT3* (rs11246002, rs2293168, rs3216, rs10081, rs511744, rs6598074, rs4758633, rs11246007, rs3782117, rs3782116, rs3782115, rs1023430, rs12576565, rs536715, rs3829998), 7 in *SIRT4* (rs6490288, rs7298516, rs3847968, rs12424555, rs7137625, rs2261612, rs2070873), 11 in *SIRT5* (rs2804923, rs9382227, rs2804916, rs2804918, rs9370232, rs4712047, rs3734674, rs11751539, rs3757261, rs2253217, rs2841514), and 4 in *SIRT6* (rs350852, rs7246235, rs107251, rs350844). We could not identify any confirmed SNPs within *SIRT7* in the Japanese population. The genotyping of these SNPs was performed by using multiplex polymerase chain reaction (PCR)-invader assays, as described previously \[[@CR7]--[@CR10]\].

Statistical analyses {#Sec8}
--------------------

We tested the genotype distributions for Hardy--Weinberg equilibrium (HWE) proportions by using the chi-squared test. We analyzed the differences between the case−control groups in terms of the distribution of genotypes with the Cochran--Armitage trend test. The analyses for haplotype structures within each gene were performed using Haploview software version 4.1 \[[@CR20]\]. A combined meta-analysis was performed using the Mantel--Haenszel procedure with a fixed effects model after testing for heterogeneity.

Results {#Sec9}
=======

Among the 55 SNPs examined, genotype distributions of 3 SNPs, rs12576565 in *SIRT3*, and rs2804923 and rs2841514 in *SIRT 5*, showed significant deviation from HWE proportion in control groups (*P* \< 0.01, Supplementary Table 2), and these 3 SNPs were excluded from the association study. As shown in Table [1](#Tab1){ref-type="table"}, 8 out of 11 SNPs in *SIRT1* showed a directionally consistent association with diabetic nephropathy in all 3 studies, although individual associations were not significant (*P* \> 0.05, Supplementary Table 2). In a combined meta-analysis, we could identify a nominally significant association between rs4746720 and proteinuria, and between 4 SNPs, rs2236319, rs10823108, rs3818292, rs4746720, and combined phenotypes (proteinuria + ESRD, *P* \< 0.05). Subsequent haplotype analysis revealed that the 11 SNPs formed one haplotype block (Fig. [1](#Fig1){ref-type="fig"}), and 7 common haplotypes covered \>99% of the present Japanese population. Among them one haplotype had a stronger association with diabetic nephropathy than single SNPs alone (*P* = 0.016, odds ratio (OR) 1.31 95% confidence interval (CI) 1.05--1.62\]. Any SNPs or haplotypes in *SIRT2*--*6* were not associated with diabetic nephropathy in the combined analysis (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}), although there was an association between 3 SNPs (rs4712047, rs3734674, rs3757261) in *SIRT5* and diabetic nephropathy in the study 2 population (Supplementary Table 2). To validate the association between *SIRT1* and diabetic nephropathy, we examined another 195 cases (overt proteinuria) and 264 controls registered in the BioBank Japan (study 4). As shown in Table [7](#Tab7){ref-type="table"}, most SNPs showed a consistent association with those in the original finding, and the association of the haplotype was strengthened further (*P* = 0.0028, OR 1.36, 95% CI 1.11--1.66). We further examined the association between *SIRT1* SNPs and microalbuminuria in studies 1 and 2, but could not identify a significant association (Supplementary Table 3), suggesting *SIRT1* SNPs might contribute to the progression of nephropathy rather than its onset in patients with type 2 diabetes.Table 1Association between SNPs in *SIRT1* and diabetic nephropathyAllele frequencies (nephropathy case−control)ProteinuriaESRDCombinedStudy 1Study 2*P*OR (95% CI)Study 3*P*OR (95% CI)SNP rs12778366^a^ T\>C0.111/0.1030.125/0.1240.6721.04 (0.86--1.26)0.101/0.1190.9810.998 (0.84--1.18) rs3740051^a^ A\>G0.291/0.2770.316/0.3010.2991.07 (0.94--1.22)0.310/0.2740.1381.09 (0.97--1.23) rs2236318^a^ T\>A0.121/0.1290.099/0.1110.3270.91 (0.75--1.10)0.106/0.1190.2360.90 (0.76--1.07) rs2236319 A\>G0.339/0.3170.358/0.3390.1651.09 (0.96--1.24)0.349/0.3000.0481.12 (1.00--1.26) rs10823108 G\>A0.335/0.3180.357/0.3350.1691.09 (0.96--1.24)0.351/0.3020.0491.12 (1.00--1.26) rs10997868^a^ C\>A0.187/0.1840.187/0.1740.5201.05 (0.90--1.23)0.180/0.1730.4821.05 (0.91--1.21) rs2273773 T\>C0.339/0.3250.361/0.3470.3251.07 (0.94--1.21)0.353/0.3060.1131.10 (0.98--1.23) rs3818292 A\>G0.336/0.3170.360/0.3350.1341.10 (0.97--1.25)0.352/0.3060.0421.13 (1.00--1.26) rs3818291 G\>A0.111/0.1010.127/0.1290.6501.04 (0.87--1.26)0.101/0.1240.9270.99 (0.84--1.17) rs4746720^a^ T\>C0.366/0.3940.331/0.3640.0410.88 (0.77--0.99)0.367/0.4000.0210.88 (0.78--0.98) rs10823116^a^ A\>G0.446/0.4420.441/0.4480.9050.99 (0.88--1.12)0.459/0.3940.4281.05 (0.94--1.16)Haplotype TGTGACCGGTG0.294/0.2790.316/0.3000.2501.08 (0.95--1.23)0.315/0.2730.0951.10 (0.98--1.24) TATAGCTAGCA0.255/0.2730.251/0.2520.4640.95 (0.83--1.09)0.253/0.3040.1430.91 (0.81--1.03) CATAGCTAATA0.112/0.1030.124/0.1290.8171.02 (0.85--1.23)0.100/0.1190.8410.98 (0.83--1.16) TAAAGATAGTA0.123/0.1280.104/0.1120.4840.94 (0.78--1.13)0.105/0.1220.3190.92 (0.78--1.08) TATAGCTAGCG0.109/0.1230.085/0.1110.0370.81 (0.67--0.99)0.113/0.0990.1170.87 (0.73--1.03) TATAGATAGTA0.065/0.0550.078/0.0590.0511.27 (0.998--1.61)0.077/0.0530.0161.31 (1.05--1.62) TATGACCGGTG0.042/0.0390.040/0.0360.571.09 (0.81--1.48)0.036/0.0280.4211.12 (0.85--1.48)^a^Tag SNPs Fig. 1Position of the 11 SNPs in *SIRT1*, and pair-wise linkage disequilibrium coefficients (*r* ^2^) among 11 SNPs in the present Japanese population Table 2Association between SNPs in *SIRT2* and diabetic nephropathyAllele frequencies (nephropathy case−control)ProteinuriaESRDCombinedStudy 1Study 2*P*OR (95% CI)Study 3*P*OR (95% CI)SNP rs1001413^a^ G\>A0.381/0.3590.353/0.3610.5941.03 (0.91--1.17)0.342/0.3890.8370.99 (0.88--1.11) rs892034^a^ C\>T0.193/0.1660.180/0.1690.0991.14 (0.98--1.34)0.164/0.1940.3521.07 (0.93--1.23) rs2015^a^ A\>C0.398/0.4000.389/0.4060.5500.96 (0.85--1.09)0.384/0.3910.5220.96 (0.86--1.08) rs2241703^a^ G\>A0.235/0.2260.222/0.2150.5341.05 (0.91--1.21)0.219/0.2080.4531.05 (0.92--1.20) rs2082435^a^ C\>G0.247/0.2620.260/0.2700.3650.94 (0.82--1.08)0.256/0.2310.6780.97 (0.86--1.10) rs11575003^a^ T\>C0.118/0.1150.126/0.1320.8860.99 (0.82--1.18)0.132/0.1190.8871.01 (0.86--1.19) rs2053071^a^ G\>C0.377/0.3980.384/0.3960.2600.93 (0.82--1.05)0.426/0.4020.5060.96 (0.86--1.08)Haplotype Block 1  CCGG0.243/0.2580.245/0.2680.1360.90 (0.79--1.03)0.254/0.2260.3660.95 (0.84--1.07)  CAAC0.231/0.2220.227/0.2160.4381.06 (0.92--1.22)0.218/0.2040.3471.06 (0.94--1.21)  CAGC0.179/0.2120.207/0.2060.1860.91 (0.78--1.05)0.232/0.2050.4770.95 (0.84--1.09)  TAGC0.191/0.1650.191/0.1690.0371.18 (1.01--1.37)0.164/0.1970.1961.10 (0.95--1.26)  CCGC0.154/0.1420.127/0.1400.9930.999 (0.84--1.18)0.130/0.1640.4970.95 (0.81--1.04) Block 2  TG0.620/0.5970.614/0.5990.1911.08 (0.96--1.22)0.568/0.5850.3461.05 (0.95--1.17)  TC0.262/0.2880.256/0.2700.1420.91 (0.79--1.03)0.300/0.2950.1210.91 (0.81--1.02)  CC0.114/0.1100.126/0.1270.8501.02 (0.85--1.22)0.127/0.1090.5861.05 (0.89--1.23)Block 1; rs892034, rs2015, rs2241703, rs2082435Block 2; rs11575003, rs2053071^a^Tag SNPs Table 3Association between SNPs in *SIRT3* and diabetic nephropathyAllele frequencies (nephropathy case−control)ProteinuriaESRDCombinedStudy 1Study 2*P*OR (95% CI)Study 3*P*OR (95% CI)SNP rs11246002^a^ G\>A0.137/0.1230.152/0.1370.1691.13 (0.95--1.34)0.122/0.1100.1381.13 (0.96--1.32) rs2293168 G\>A0.356/0.3620.385/0.4020.4400.95 (0.84--1.08)0.400/0.3720.7760.98 (0.88--1.10) rs3216 C\>G0.172/0.1680.160/0.1550.7421.03 (0.87--1.21)0.152/0.1920.6550.97 (0.84--1.12) rs10081^a^ A\>G0.507/0.5150.464/0.4630.8051.02 (0.90--1.15)0.460/0.5140.3380.95 (0.85--1.06) rs511744^a^ C\>T0.488/0.4820.469/0.4850.7780.98 (0.87--1.11)0.491/0.4870.8530.99 (0.89--1.10) rs6598074 T\>C0.164/0.1610.126/0.1350.7970.98 (0.82--1.16)0.154/0.1440.9630.996 (0.86--1.16) rs4758633^a^ G\>A0.347/0.3550.288/0.2940.5990.97 (0.85--1.10)0.319/0.3490.3600.94 (0.84--1.06) rs11246007^a^ C\>T0.143/0.1550.149/0.1520.4710.94 (0.79--1.11)0.142/0.1430.5120.95 (0.82--1.11) rs3782117^a^ A\>G0.168/0.1710.160/0.1530.8431.02 (0.86--1.20)0.152/0.1930.5440.96 (0.83--1.11) rs3782116^a^ G\>A0.307/0.2940.278/0.2720.5071.05 (0.92--1.19)0.292/0.2680.3331.06 (0.94--1.20) rs3782115^a^ C\>T0.283/0.2830.265/0.2570.7851.02 (0.89--1.17)0.263/0.2410.9641.04 (0.92--1.17) rs1023430^a^ A\>G0.291/0.3020.325/0.3070.8491.01 (0.89--1.15)0.285/0.2750.7431.02 (0.91--1.15) rs536715^a^ G\>A0.367/0.3670.395/0.4060.7360.98 (0.86--1.11)0.404/0.3890.9390.996 (0.89--1.11) rs3829998^a^ G\>A0.167/0.1670.124/0.1390.5290.95 (0.80--1.12)0.160/0.1530.6740.97 (0.83--1.13)Haplotype Block 1  GACT0.354/0.3620.378/0.3980.3420.94 (0.83--1.06)0.403/0.3770.6350.97 (0.87--1.09)  GGCC0.335/0.3460.310/0.3090.7000.98 (0.86--1.11)0.317/0.3210.6880.97 (0.87--1.09)  GGGC0.172/0.1680.159/0.1540.6881.03 (0.88--1.21)0.151/0.1920.6780.97 (0.84--1.12)  AGCT0.138/0.1230.151/0.1370.1711.27 (0.95--1.34)0.124/0.1100.1271.13 (0.97--1.11) Block 2  TGGA0.519/0.5110.560/0.5560.7101.02 (0.91--1.15)0.550/0.5210.4621.04 (0.94--1.16)  TAGG0.171/0.1690.158/0.1530.7651.02 (0.87--1.20)0.151/0.1920.6220.96 (0.84--1.11)  TGAA0.143/0.1550.150/0.1520.490.94 (0.80--1.11)0.142/0.1420.5400.95 (0.82--1.11)  CAGA0.167/0.1640.131/0.1360.9520.99 (0.84--1.17)0.157/0.1460.8680.95 (0.82--1.11) Block 3  AAG0.364/0.3630.383/0.4020.5470.96 (0.85--1.09)0.403/0.3840.7790.98 (0.88--1.10)  GGG0.287/0.2970.320/0.3030.8011.02 (0.89--1.16)0.281/0.2650.6401.03 (0.92--1.15)  AGG0.177/0.1700.157/0.1520.6181.04 (0.89--1.22)0.154/0.1910.8090.98 (0.85--1.13)  AGA0.168/0.1660.133/0.1400.8560.98 (0.84--1.16)0.158/0.1520.9670.997 (0.86--1.16)Block 1; rs11246002, rs2293168, rs3216, rs10081Block 2; rs6598074, rs4758633, rs11246007, rs3782117Block 3; rs1023430, rs536715, rs3829998^a^Tag SNPs Table 4Association between SNPs in *SIRT4* and diabetic nephropathyAllele frequencies (nephropathy case−control)ProteinuriaESRDCombinedStudy 1Study 2*P*OR (95% CI)Study 3*P*OR (95% CI)SNP rs6490288 G\>C0.068/0.0760.076/0.0770.5740.94 (0.74--1.18)0.080/0.0660.8800.98 (0.80--1.21) rs7298516^a^ T\>G0.009/0.0090.008/0.0110.6080.85 (0.46--1.58)0.017/0.0160.7140.91 (0.54--1.53) rs3847968^a^ C\>T0.187/0.1840.187/0.1740.4500.91 (0.71--1.16)0.180/0.1730.8061.03 (0.82--1.28) rs12424555 C\>T0.059/0.0690.065/0.0690.3660.89 (0.70--1.14)0.071/0.0460.9120.99 (0.79--1.23) rs7137625^a^ C\>T0.057/0.0400.058/0.0560.1411.23 (0.94--1.60)0.045/0.0630.4351.10 (0.87--1.40) rs2261612 A\>G0.473/0.4840.457/0.4760.3380.94 (0.84--1.06)0.476/0.4590.5320.97 (0.87--1.08) rs2070873^a^ T\>G0.469/0.4760.457/0.4740.4430.95 (0.85--1.08)0.480/0.4680.6000.97 (0.87--1.08)Haplotype Block 1  CCCAT0.527/0.5180.546/0.5200.2451.07 (0.95--1.21)0.517/0.5320.4001.05 (0.94--1.16)  CCCGG0.350/0.3680.326/0.3480.1540.91 (0.81--1.03)0.360/0.3420.3050.94 (0.84--1.05)  TTCGG0.058/0.0670.065/0.0620.6950.95 (0.75--1.21)0.067/0.0520.9321.01 (0.81--1.26)  CCTGG0.056/0.0390.056/0.0560.1811.20 (0.92--1.56)0.046/0.0630.5011.08 (0.86--1.38)Block 1; rs3847968, rs12424555, rs7137625, rs2261612, rs2070873^a^Tag SNPs Table 5Association between SNPs in *SIRT5* and diabetic nephropathyAllele frequencies (nephropathy case−control)ProteinuriaCombinedStudy 1Study 2*P*OR (95% CI)Study 3*P*OR (95% CI)SNP rs9382227^a^ G\>T0.188/0.1960.218/0.1920.4941.05 (0.91--1.22)0.198/0.2100.6881.03 (0.90--1.18) rs2804916^a^ T\>C0.170/0.1660.157/0.1630.9210.99 (0.84--1.17)0.138/0.1350.9710.997 (0.86--1.16) rs2804918^a^ A\>G0.345/0.3570.352/0.3330.8471.01 (0.89--1.15)0.318/0.3210.8961.01 (0.90--1.13) rs9370232^a^ G\>C0.361/0.3700.358/0.3620.6400.97 (0.86--1.10)0.357/0.3460.7970.99 (0.88--1.10) rs4712047^a^ G\>A0.494/0.4770.448/0.5050.2210.93 (0.82--1.05)0.456/0.4570.2690.94 (0.84--1.05) rs3734674 G\>A0.158/0.1710.191/0.1490.2521.10 (0.93--1.29)0.176/0.1880.4161.06 (0.92--1.23) rs11751539^a^ A\>T0.309/0.3200.302/0.3120.4760.95 (0.84--1.09)0.315/0.2760.9550.997 (0.87--1.12) rs3757261^a^ G\>A0.155/0.1650.184/0.1390.1591.12 (0.95--1.32)0.168/0.1740.2521.09 (0.94--1.26) rs2253217^a^ A\>G0.063/0.0710.056/0.0680.2100.85 (0.67--1.09)0.045/0.0610.1110.83 (0.67--1.04)Haplotype Block 1  GT0.641/0.6370.629/0.6450.6660.97 (0.86--1.10)0.665/0.6550.7960.99 (0.88--1.10)  TT0.189/0.1960.215/0.1920.5191.05 (0.91--1.22)0.198/0.2100.7111.03 (0.90--1.17)  GC0.171/0.1670.156/0.1630.0860.87 (0.74--1.02)0.137/0.1350.9490.995 (0.86--1.15) Block 2  GAGA0.471/0.4420.446/0.4780.9040.99 (0.88--1.12)0.468/0.4910.6740.98 (0.88--1.09)  GTGA0.311/0.3200.313/0.3120.7580.98 (0.86--1.11)0.313/0.2720.7341.02 (0.91--1.14)  AAAA0.154/0.1660.184/0.1390.1501.12 (0.96--1.32)0.169/0.1740.2391.09 (0.94--1.26)  GAGG0.061/0.0670.054/0.0610.3530.89 (0.70--1.14)0.042/0.0500.2800.88 (0.70--1.11)Block 1; rs9382227, rs2804916Block 2; rs3734674, rs11751539, rs3757261, rs2253217, rs2841514^a^Tag SNPs Table 6Association between SNPs in *SIRT6* and diabetic nephropathyAllele frequencies (nephropathy case−control)ProteinuriaESRDCombinedStudy 1Study 2*P*OR (95% CI)Study 3*P*OR (95% CI)SNP rs350852^a^ T\>C0.313/0.3380.313/0.3030.5450.96 (0.84--1.09)0.324/0.3480.3670.95 (0.84--1.06) rs7246235^a^ T\>G0.185/0.1860.168/0.2090.1100.88 (0.75--1.03)0.202/0.1640.4470.95 (0.82--1.09) rs107251^a^ C\>T0.296/0.3150.305/0.2910.8410.99 (0.87--1.12)0.323/0.3280.7990.98 (0.88--1.11) rs350844 G\>A0.304/0.3220.309/0.2910.9360.99 (0.87--1.13)0.336/0.3470.8190.99 (0.88--1.11)Haplotype Block 1  TCG0.516/0.4990.529/0.5000.1221.10 (0.98--1.24)0.517/0.5320.3421.05 (0.95--1.17)  TTA0.299/0.3180.303/0.2910.7760.98 (0.86--1.12)0.360/0.3420.7130.98 (0.87--1.10)  GCG0.185/0.1830.168/0.2090.1000.88 (0.76--1.02)0.067/0.0520.4330.95 (0.83--1.09)Block 1; rs7246235, rs107251, rs350844^a^Tag SNPs Table 7Replication study for the association between SNPs in *SIRT1* and diabetic nephropathyAllele frequencies (nephropathy case−control)Proteinuria (study 1, 2, 4)Proteinuria + ESRD (study 1, 2, 3, 4)Study 4*P*OR (95% CI)*P*OR (95% CI)SNP rs12778366^a^ T\>C0.089/0.1310.6760.96 (0.81--1.15)0.4480.94 (0.80--1.10) rs3740051^a^ A\>G0.311/0.2910.2261.08 (0.96--1.21)0.1061.09 (0.98--1.22) rs2236318^a^ T\>A0.113/0.1160.3500.92 (0.78--1.09)0.2570.91 (0.78--1.07) rs2236319 A\>G0.360/0.3440.1421.09 (0.97--1.22)0.0441.12 (1.00--1.24) rs10823108 G\>A0.358/0.3370.1271.09 (0.97--1.23)0.0381.12 (1.01--1.24) rs10997868^a^ C\>A0.181/0.1750.4901.05 (0.91--1.21)0.4561.05 (0.92--1.20) rs2273773 T\>C0.364/0.3420.2391.07 (0.95--1.20)0.0851.10 (0.99--1.22) rs3818292 A\>G0.358/0.3440.1201.10 (0.98--1.23)0.0401.12 (1.01--1.24) rs3818291 G\>A0.090/0.1320.6960.97 (0.81--1.15)0.4120.94 (0.80--1.10) rs4746720^a^ T\>C0.371/0.3610.0840.90 (0.81--1.01)0.0440.90 (0.81--0.997) rs10823116^a^ A\>G0.453/0.4500.9390.996 (0.89--1.11)0.4461.04 (0.94--1.15)Haplotype TGTGACCGGTG0.306/0.2970.2401.07 (0.95--1.21)0.0981.09 (0.98--1.22) TATAGCTAGCA0.269/0.2430.8090.96 (0.87--1.11)0.3360.95 (0.85--1.06) CATAGCTAATA0.105/0.1290.7410.97 (0.82--1.15)0.4960.95 (0.81--1.10) TAAAGATAGTA0.122/0.1160.6210.96 (0.81--1.13)0.4300.94 (0.80--1.09) TATAGCTAGCG0.095/0.1120.0220.82 (0.69--0.97)0.0710.86 (0.74--1.01) TATAGATAGTA0.072/0.0590.00911.34 (1.07--1.66)0.00281.36 (1.11--1.66) TATGACCGGTG0.031/0.0440.9421.01 (0.77--1.33)0.7461.04 (0.81--1.35)^a^Tag SNPs
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In the present study, we identified that SNPs within *SIRT1* were nominally associated with susceptibility to diabetic nephropathy. We also identified one haplotype consisting of the 11 SNPs in *SIRT1* had a stronger association with diabetic nephropathy than single SNPs alone.

*SIRT1* encodes a member of NAD(+)-dependent histone deacetylase, involved in various nuclear events such as transcription, DNA replication, and DNA repair. Cumulative evidence during the past decade has demonstrated that SIRT1 plays an important role not only in the regulation of aging and longevity, but also in the development and/or progression of age-associated metabolic diseases, such as type 2 diabetes. SIRT1 activation is considered to be a key mediator for favorable effects on lifespan or on metabolic activity in animals under calorie restriction (CR) \[[@CR21]--[@CR24]\]. Recently, Kume et al. \[[@CR19]\] reported that mice under 40% CR were protected from the development of glomerular sclerosis in aging mice kidneys through increasing mitochondrial biogenesis caused by sirt1 activation. From these observations, it is suggested that SIRT1 has a pivotal role in the pathogenesis of aging-related metabolic diseases, such as type 2 diabetes or glomerulosclerosis, and a genetic difference in SIRT1 activity among individuals, if it is present, may contribute to conferring susceptibility to these diseases.

In the present study, we identified that SNPs within *SIRT1* were nominally associated with diabetic nephropathy, whereas SNPs in other sirtuin families did not show any association with diabetic nephropathy. Combining the present finding with a previous report, *SIRT1* may be considered a good new candidate for diabetic nephropathy, although, the role of sirtuin families other than SIRT1 in age-related metabolic diseases has not been well evaluated. The mechanism by which the *SIRT1* polymorphism contributes to conferring susceptibility to diabetic nephropathy remains to be elucidated. Since SIRT1 could affect various metabolic activities, the effects of *SIRT1* polymorphisms on susceptibility to diabetic nephropathy might be mediated by differences in the metabolic state among individuals, including glycemic control, obesity, blood pressure, etc. We then examined the association between SNPs in *SIRT1* and BMI, hemoglobin A1c (HbA1c), fasting plasma glucose, or systolic blood pressure in the present subjects with type 2 diabetes, but we could not observe any association between the *SIRT1* SNPs and those quantitative traits (*P* \> 0.05, Supplementary Table 4). In contrast to our present finding, SNPs within the *SIRT1*, rs7895833 and rs1467568, were shown to be significantly associated with BMI in Dutch populations \[[@CR25]\]. We did not examine those SNPs, but the present study includes an SNP in high linkage disequilibrium (LD) to these 2 SNPs (rs10997868; *r* ^2^ = 1 and 0.64 to rs1467568 and rs7895833, respectively). Interestingly, there is a dramatic difference in the frequency of the reported protected allele (A allele of rs1467568) between European and Japanese populations (0.25 in the European population vs. 0.841 in the Japanese population, HapMap database, <http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1467568>). Since rs10997868 was not associated with either BMI or susceptibility to the disease, ethnic differences may contribute to the discrepancy between the Dutch and Japanese populations, and the contribution of *SIRT1* SNPs to BMI, if it is present, is considered very minor in the Japanese population. It has been also reported that SNPs in *SIRT1* were associated with energy expenditure in a small number of Finnish healthy nondiabetic offspring of patients with type 2 diabetes \[[@CR23]\]. The alleles associated with higher energy expenditure, supposed to be favorable alleles for glucose metabolism, are G for rs3740051, G for rs2236319, and C for rs2273773, respectively; although these alleles increase the risk of diabetic nephropathy in the present Japanese population. From these observations, we speculate that the effects of *SIRT1* gene polymorphisms on diabetic nephropathy are independent of these metabolic parameters; however, there are limitations to the present cross-sectional study and further longitudinal prospective studies are required to obtain a precise conclusion. The association between individual *SIRT1* SNPs and diabetic nephropathy did not attain statistically significant levels after correction for multiple-testing errors, and a haplotype consisting of 11 *SIRT1* SNPs had a stronger association with the disease, suggesting the existence of other true causal variations within this locus. In addition, since nephropathy cases in the present study were at a more advanced stages of diabetic nephropathy, the findings on SNPs and the haplotype within *SIRT1* may be applicable mainly to advanced diabetic nephropathy. Therefore, further extensive analyses for this locus, re-sequencing, dense LD mapping, or further confirmation studies are also required to link the *SIRT1* locus to the genetic susceptibility of diabetic nephropathy as a whole.

In conclusion, we found that the SNPs and a haplotype within *SIRT1* were nominally associated with susceptibility to diabetic nephropathy in four independent Japanese case--control studies. The present data suggest that *SIRT1* may be a good candidate for diabetic nephropathy, although the association should be evaluated further in independent studies.
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